J&J (JNJ) Beats On Q3 Earnings As Sales Rise, Ups 2019 View
Zacks Investment Research | Oct 14, 2019 11:10PM ET
Johnson & Johnson’s (NYSE:JNJ) third-quarter 2019 earnings came in at $2.12 per share, which beat the Zacks Consensus Estimate of $2.00 and increased 3.4% from the year-ago period.
Adjusted earnings exclude after-tax intangible amortization expense and some special items. Including these items, J&J reported third-quarter earnings of $1.81 per share, up 25.7% from the year-ago quarter.
Sales of the drug and consumer products giant came in at $20.73 billion, which beat the Zacks Consensus Estimate of $20.08 billion. Sales rose 1.9% from the year-ago quarter, reflecting an operational increase of 3.2%, which offset an unfavorable currency impact of 1.3%.
Organically, excluding the impact of acquisitions and divestitures, sales increased 5.2% on an operational basis, higher than 3.7% increase seen in the previous quarter.
Sales rose in all the three segments on an organic basis. It accelerated in the Medical Device and Pharma units but decelerated in the Consumer unit on a sequential basis mainly due to lower sales of baby care products.
Third-quarter sales rose 1.2% in the domestic market to $10.79 billion and 2.6% in international markets to $9.94 billion. However, international sales reflected 5.4% operational growth, which was offset by 2.8% negative currency impact.
Segment Details
Pharmaceutical segment sales rose 5.1% year over year to $10.88 billion, reflecting 6.4% operational growth which was offset by 1.3% negative currency impact. Excluding the impact of all acquisitions and divestitures, on an operational basis, worldwide sales increased 6.4%, improving from 4.4% increase in the previous quarter.
The sales increase was led by the company’s oncology drugs, Imbruvica and Darzalex as well as psoriasis treatment, Stelara.
Worldwide sales of J&J’s oncology drugs rose 6.7% in the quarter to $2.76 billion. Other core products like Stelara, Simponi/Simponi Aria and Invega Sustenna and new immunology medicines like Tremfya also contributed to growth. However, sales of some other key drugs like Xarelto were soft in the quarter. Sales of others like Zytiga, Remicade, Procrit/Eprex declined due to the impact of generic/biosimilar competition.
Darzalex sales rose 53.5% year over year to $765 million in the quarter. Stelara sales rose 29.6% to $1.7 billion in the quarter. Imbruvica sales rose 30.6% to $921 million in the quarter. Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. (NYSE:ABBV) . Invega Sustenna sales rose 13.7% to $851 million in the quarter.
Simponi/Simponi Aria sales rose 9.6% to $586 million in the quarter. Newly launched Tremfya recorded sales of $290 million in the quarter compared with $235 million in the second quarter.
Zytiga sales declined 22.7% to $741 million in the quarter as growth outside the United States was offset by sales decline in the United States due to generic competition.
Sales of Invokana/Invokamet declined 5.8% to $179 million. Xarelto sales were almost flat in the quarter at $613 million. Sales of Procrit/Eprex declined 22.4% to $198 million in the quarter. Sales of Remicade were down 17.6% in the quarter to $1.14 billion. Please note that J&J markets Remicade in partnership with Merck (NYSE:MRK) .
In the quarter, J&J recorded pulmonary arterial hypertension revenues of $654 million, down 0.3% year over year. Strong demand for Uptravi and Opsumit was offset by a decline in Tracleer sales. We remind investors that Teva Pharmaceutical Industries Limited (NYSE:TEVA) launched a generic version of Tracleer in the United States in June.
Medical Devices segment sales came in at $6.38 billion, down 3.1% from the year-ago period, reflecting an operational decrease of 2.0% and negative currency movement of 1.1%.
Excluding the impact of all acquisitions and divestitures, on an operational basis, worldwide sales increased 5.3%, better than 3.2% in the previous quarter.
The Consumer segment recorded revenues of $3.47 billion in the reported quarter, up 1.6% year over year. On an operational basis, Consumer segment sales increased 3.3%, partially offset by unfavorable foreign currency movement of 1.7%.
Excluding the impact of acquisitions and divestitures, adjusted operational sales growth was 1.3% worldwide, a deceleration from 2.3% the previous quarter.
2019 Guidance
J&J raised its full-year earnings and sales view on strong third quarter results.
Adjusted earnings per share in 2019 are expected in the range of $8.62 - $8.67, up from the prior range of $8.53 - $8.63. The guidance range indicates growth of 5.4-6% (previously 4.3-5.5%). On an operational, constant currency basis, adjusted earnings per share are expected to grow in the range of 8.1 - 8.7%, up from the prior expectation of 6.7-7.9%.
Revenues are expected in the range of $81.8-$82.3 billion, up from the previous range of $80.8-$81.6 billion, including currency impact.
Operational constant currency sales growth is expected to be in the range of 2.5%-3%, better than 1%-2% expected previously. Adjusted operational sales growth, (excluding currency impact, acquisitions/divestitures) is expected to be in the range of 4.5% to 5%, higher than 3.2% to 3.7% expected previously.
Our Take
J&J beat third-quarter estimates for both earnings and sales and raised its financial outlook for the year, which pushed its shares up more than 2% in pre-market trading. The stock has returned 1.3% this year so far against a decrease of 0.8% recorded by the .
Get The News You Want
Johnson & Johnson Price, Consensus and EPS Surprise
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.